Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Vergiss die Indizes - Forge steigt um 40 %, während der S&P & Dow fällt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14Z8X | ISIN: SE0007464862 | Ticker-Symbol: Q3I
Frankfurt
25.04.25
08:08 Uhr
0,110 Euro
+0,007
+6,59 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ADDVISE GROUP AB Chart 1 Jahr
5-Tage-Chart
ADDVISE GROUP AB 5-Tage-Chart

Aktuelle News zur ADDVISE GROUP Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoNew equity right for trading, ADDvise Group AB44At the request of ADDvise Group AB, equity rights will be traded on First North Growth Market as from 25 April 2025. Security name: ADDvise Group AB TO 1 A Short...
► Artikel lesen
ADDVISE GROUP Aktie jetzt für 0€ handeln
09.04.Notice to the annual general meeting of ADDvise Group AB (publ)1
08.04.ADDVISE GROUP AB: ADDvise raises approximately SEK 457 million in the rights issue3
08.04.ADDVISE GROUP AB: ADDvise Group publishes annual report and sustainability report for 20244
07.04.ADDVISE GROUP AB: ADDvise announces preliminary outcome of the rights issue2
20.03.ADDVISE GROUP AB: ADDvise publishes prospectus in connection with a rights issue4
18.03.XFRA CAPITAL ADJUSTMENT INFORMATION - 18.03.2025378Das Instrument 0A3 NL0015000RT3 NEPI ROCKCASTLE EO -,01 EQUITY wird cum Kapitalmassnahme gehandelt am 18.03.2025 und ex Kapitalmassnahme am 19.03.2025 The instrument 0A3 NL0015000RT3 NEPI ROCKCASTLE...
► Artikel lesen
12.03.ADDvise Group AB (publ): Report from the extra ordinary general meeting in ADDvise Group AB (publ)250ADDvise Group AB (publ), reg. no. 556363-2115 (the "Company"), has held an extraordinary general meeting on 12 March 2025. The general meeting resolved to amend the articles of association, approve...
► Artikel lesen
20.02.ADDvise Group AB (publ): Year-end report 2024, January 1-December 3195The fourth quarter of 2024 showed a turnaround in organic net revenue. In December alone, we are now back at positive organic growth of 4.8%. With new long-term financial targets, we are now taking...
► Artikel lesen
07.02.Notice to extraordinary general meeting of ADDvise Group AB (publ)4
07.02.ADDVISE GROUP AB: The Board of Directors of ADDvise has resolved on a rights issue of SEK 457 million3
07.02.ADDvise Group AB (publ): ADDvise presents preliminary financial information for the fourth quarter of 2024 and updates long-term financial targets119The Board of Directors of ADDvise Group AB ("ADDvise" and the "Company") presents preliminary financial information for the fourth quarter of 2024 and has, in connection therewith, decided to update...
► Artikel lesen
06.02.ADDVISE GROUP AB: Invitation to presentation of interim report October 1 - December 31, 20243
06.12.24ADDVISE GROUP AB: ADDvise receives allocation decision worth approximately SEK 72 million10
11.11.24ADDVISE GROUP AB: ADDvise explores potential divestment of its subsidiary Germa9
11.11.24ADDVISE GROUP AB: ADDvise receives order worth USD 1.8 million3
28.10.24ADDvise Group AB (publ): ADDvise streamlines organization through new business area structure166To enhance focus and efficiency, ADDvise is restructuring its two existing business areas, Lab and Healthcare, into separate operational units, each led by a dedicated director. This new structure is...
► Artikel lesen
24.10.24ADDvise Group AB (publ): Interim report 2024, January 1-September 30147The third quarter of 2024 showed strong order intake, +17%, and net revenue growth, +26%. Despite challenging comparative figures from 2023, especially in the pharmaceutical sector and rental of equipment...
► Artikel lesen
18.07.24ADDvise Group AB (publ): Interim report 2024, January 1 - June 30131The second quarter saw continued robust revenue growth and improved profit. Organic growth remains burdened by challenging comparables from 2023 driven by very strong sales in pharmaceuticals and rental...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1